Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
11. Combination Treatment Boosts Survival in Biliary Tract Cancers
(Posted: 06/19/2009) - Patients who received the chemotherapy drugs cisplatin and gemcitabine for advanced, inoperable biliary tract cancers lived several months longer than patients who received gemcitabine alone, according to findings presented at the 2009 ASCO meeting in Orlando.
12. Sorafenib Delays Progression of Metastatic Kidney Cancer
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
13. Adding Temozolomide (Temodar®) to Radiation Increases Survival in Glioblastoma Multiforme
(Posted: 06/07/2004, Updated: 06/01/2009) - The survival benefit obtained by adding the drug temozolomide (Temodar®) to postoperative radiation therapy in the treatment of a brain tumor called glioblastoma multiforme persists over time, according to the March 9 issue of Lancet Oncology.
14. Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients
(Posted: 02/12/2008, Updated: 06/01/2009) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.
15. Maintenance Rituximab May Improve Survival in Follicular Lymphoma
(Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.
< Previous 1 2 3 4 5 6 Next >
|
